[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-polyp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-polyp":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,70,99,129,160,191,214,241,267,288,313,332,352,379,407,436,460,484,509,532],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":44,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100542405","early-detection-of-advanced-adenomas-and-colorectal-cancer-100542405",false,"NCT06342440","Early Detection of Advanced Adenomas and Colorectal Cancer","A Liquid Biopsy Assay For The Non-Invasive Early Detection of Advanced Adenomas and Colorectal Cancer","AACRC","Inclusion Criteria:\n\n* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.\n* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Received standard pathological and endoscopic diagnosis and assessment for cohort assignment.\n\nExclusion Criteria:\n\n* Hereditary colorectal cancer syndromes (identified through genetic testing).\n* Inflammatory bowel diseases.\n* Lack of written informed consent.",true,"ALL","18 Years",{"count":21,"type":22},2000,"ESTIMATED","OBSERVATIONAL","This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Colorectal Cancer","Colorectal Neoplasms","Colorectal Polyp","Colorectal Adenocarcinoma","Colorectal Disorders","Colorectal Dysplasia","Colorectal Cancer Stage I","Colorectal Cancer Stage II","Colorectal Cancer Stage III","Colorectal Cancer Stage IV","Colorectal Neoplasms Malignant","Colorectal Serrated Adenocarcinoma","Colorectal Adenoma With Severe Dysplasia","Colorectal Adenoma With Mild Dysplasia","Colorectal Adenoma With Moderate Dysplasia","Colorectal Adenoma and Carcinoma 1","Colorectal Adenomatous Polyp","Colorectal Adenocarcinoma Metastatic in the Liver",[45,46,47,48,49,50,51,52,53,54,55,56],"Early detection","Micro RNA","miRNA","Liquid biopsy","Machine learning","Artificial Intelligence","Incidence","Polypectomy","Screening","Surveillance","Exosome","Vascicles","RECRUITING","2026-06-15",{"date":60,"type":61},"2026-06-17","ACTUAL",{"date":63,"type":61},"2020-03-15",{"date":65,"type":22},"2026-06-18",{"name":67,"class":68},"City of Hope Medical Center","OTHER",6,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100425751","effects-of-unicla-a2-dairy-products-on-patients-at-high-risk-of-colorectal-cancer-development-100425751","NCT04824053","Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development","Comparative Analysis of the Effects of UNICLA-A2 Against Conventional Dairy Products Administered Daily in Patients at High-risk Colorectal Cancer Development Who Have Undergone Polypectomy","Inclusion Criteria:\n\n1. Participants diagnosed with high-risk polyps in the colorectal cancer screening programme or in the relative's colon cancer prevention program or patients who are in follow-up due to prior detection of polyps with any of the following characteristics:\n\n   * At least 10 adenomas\n   * At least 5 proximal serrated polyps (PSP)\n   * At least 2 serrated polyps with diameters ≥10 mm\n   * Serrated Polyposis Syndrome (SPS)\n   * Early invasive CRC (stage pT1) endoscopically resected (surgery not required)\n   * A sessile or flat lesion ≥ 20 mm with fragmented resection\n   * Patients with previous resection of polyps in which the resection margin was not assessable and are considered susceptible to repeat colonoscopy\n   * Patients with intramucosal carcinoma in situ or invasion of the lamina propria (pTis)\n2. Regular consumer of milk and dairy products.\n3. Informed consent form signed.\n\nExclusion Criteria:\n\n1. History of allergic reaction attributed to compounds of similar chemical composition to the study agents.\n2. Incomplete colonoscopy or with poor quality criteria, Boston \\\u003C6.\n3. Concomitant acetylsalicylic acid (ASA), NSAIDs, misoprostol, corticosteroids or statins needed on a regular or predictable basis during the time of the study.\n4. Previous gastrointestinal surgery (colon or small intestine or gastric) that affects the absorption of nutrients.\n5. History of familial adenomatous polyposis.","80 Years",{"count":79,"type":22},34,"INTERVENTIONAL",[82],"NA","Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomy",[28],[86,87,88],"polyp","inflammation","fecal microbiota","2026-05-08",{"date":91,"type":61},"2026-05-12",{"date":93,"type":61},"2022-02-28",{"date":95,"type":22},"2028-12-15",{"name":97,"class":68},"Instituto de Investigación Sanitaria Aragón",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":18,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":80,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100486305","colonoscopy-vs-stool-testing-for-older-adults-with-colon-polyps-100486305","NCT05612347","Colonoscopy vs Stool Testing for Older Adults With Colon Polyps","Colonoscopy Versus Stool-based Testing for Older Adults With a History of Colon Polyps","COOP","Inclusion Criteria:\n\n* English or Spanish speaking\n* Personal history of colorectal polyps\n* Most recent colonoscopy with ≤2 non-advanced polyps\n* Currently due or coming due within 12 months for colonoscopy\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Personal history of colorectal cancer\n* Personal history of genetic syndrome with high risk for colorectal cancer (e.g. Lynch Syndrome, Familial Adenomatous Polyposis Syndrome (FAP), or Serrated Polyposis Syndrome)\n* Personal history of inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease)\n* Most recent colonoscopy with advanced polyp(s) or ≥3 non-advanced polyps\n* Patients unlikely to benefit from polyp surveillance (e.g., history of heart disease or coronary artery disease with treatment in the last 6 months, heart failure affecting function, lung disease requiring use of home oxygen, stroke within the last 4 months, dementia affecting activities of daily living (ADL) or instrumental activities of daily living (IADL), severe liver disease requiring the use of certain medications to control fluid, confusion, or bleeding, severe kidney disease requiring dialysis, or a new cancer diagnosis within the last year)\n* Patients unable to provide written informed consent","65 Years","82 Years",{"count":110,"type":22},8946,[82],"This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.",[28,27,114,26,115],"Colorectal Adenoma","Digestive System Disease",[117,118],"Colonoscopy","Fecal immunochemical test (FIT)","2026-05-01",{"date":121,"type":61},"2026-05-07",{"date":123,"type":61},"2023-06-14",{"date":125,"type":22},"2035-12-31",{"name":127,"class":68},"Dartmouth-Hitchcock Medical Center",22,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":80,"phases":138,"briefSummary":140,"conditions":141,"keywords":146,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100498909","phase-2-the-impact-of-a-patient-decision-aid-on-treatment-choices-for-patients-with-an-unexpected-malignant-colorectal-polyp-100498909","NCT05776381","The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp","The Impact of an In-consultation Patient Decision Aid on Treatment Choices and Outcomes of Management for Patients With an Unexpected Malignant Colorectal Polyp A Non-randomized Clinical Phase II Study","Inclusion Criteria:\n\n* Histopathologically verified malignant colorectal polyp removed endoscopically and CT-scan (and MRI if the malignant polyp was situated in the rectum) shows N0, M0 disease.\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inoperable due to comorbidity\n* Known residual tumor left in situ after local resection, \\>N0 or \\>M0",{"count":137,"type":22},110,[139],"PHASE2","Management of unexpected malignant colorectal polyps removed endoscopically can be challenging due to the risk of residual tumor and lymphatic spread. International studies have shown that in patients choosing surgical management instead of watchful waiting, 54-82% of bowel resections are without evidence of residual tumor or lymphatic spread. As surgical management entails risks of complications and watchful waiting management entails risks of residual disease or recurrence, a clinical dilemma arises when choosing a management strategy.\n\nShared decision making (SDM) is a concept that can be used in preference sensitive decision making to facilitate patient involvement, empowerment, and active participation in the decision making process.\n\nThis is a clinical multicenter, non-randomized, interventional phase II study involving Danish surgical departments planned to commence in the first quarter of 2024. The aim of the study is to examine whether shared decision making and using a patient decision aid (PtDA) in consultations affects patients' choice of management compared with historical data. The secondary aim is to investigate Patient Reported Experience Measures (PREMs) and Patient Reported Outcome Measures (PROMs) using questionnaire feedback directly from the patients.",[142,143,144,145,28,26],"Shared Decision Making","Colonic Polyp","Decision Aids","Rectal Polyp",[147,148,149,142],"non-randomized trial","malignant colorectal polyp","Patient Decision aid","NOT_YET_RECRUITING","2026-04-29",{"date":153,"type":61},"2026-04-30",{"date":155,"type":22},"2028-02-01",{"date":157,"type":22},"2033-02-01",{"name":159,"class":68},"Vejle Hospital",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":18,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":80,"phases":171,"briefSummary":172,"conditions":173,"keywords":179,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":69},"100526334","paradigm---en-bloc-trial-with-the-endoquest-endoluminal-surgical-els-system-100526334","NCT06133387","PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System","PARADIGM Study: Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System","PARADIGM","Preoperative Inclusion Criteria:\n\n1. Subject is ≥22 years at the time of consent.\n2. Subject has a BMI ≤ 50 kg\u002Fm2.\n3. Subject has an ASA score of ≤ 3.\n4. Subject has benign lesion(s) of the rectum or sigmoid colon, such as adenoma (with low- or high-grade dysplasia), neuroendocrine tumor, or other type of polyp as assessed by the most recent colonoscopy\u002Fflexible sigmoidoscopy.\n5. Subject has lesion ≤ 7 cm in size (dimension of greatest extent) and ≤ 75% of the colorectal circumference as assessed by the most recent colonoscopy\u002Fflexible sigmoidoscopy.\n6. Subject is eligible for standard endoscopic submucosal dissection.\n7. Subject agrees to participate in the study by giving signed informed consent.\n\nPreoperative Exclusion Criteria:\n\n1. Subject anatomy is unsuitable for endoscopic visualization or endoluminal surgery.\n2. Subject has active left-sided inflammatory bowel disease.\n3. Subject has an untreated active infection at the time of the procedure.\n4. Subject is considered part of a vulnerable population (e.g., prisoners, mentally disabled).\n5. Subject has a severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions (e.g., cancer).\n6. Subject is breastfeeding or pregnant or intends to become pregnant during the study.\n7. Subject is currently enrolled in or discontinued within the last 30 days from a clinical trial of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.\n8. Subject with EF ≤ 45, high cardiac or high pulmonary risk (these subjects require clearance from a cardiologist and pulmonologist, as applicable).\n9. Subject on preoperative blood thinners, such as coumadin or heparin, that cannot be weaned prior to surgery.\n10. Subject is moderately or severely immunocompromised.\n11. In the opinion of the Investigator, the subject is unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.\n\nIntraoperative Exclusion Criteria (assessed with third-party endoscope):\n\n1. Inadequate bowel prep.\n2. Complex anatomical findings not feasible for an endoluminal approach.\n3. Anatomical narrowing distal to the lesion site.\n4. Lesion not located in the rectum or sigmoid colon.\n5. Lesion size \\>7 cm (dimension of greatest extent) or occupies \\>75% of the colorectal circumference.\n6. Lesion demonstrates characteristics indicative of invasive carcinoma, such as failure to lift upon submucosal injection, or any other features that raise the Investigator's suspicion of cancer.\n\n   Intraoperative Exclusion Criteria (assessed with study device):\n7. In the opinion of the Investigator, the subject and\u002For subject anatomy is not suitable for study device use for any reason.\n8. Lesion location not accessible by the study device.","22 Years",{"count":170,"type":22},56,[82],"The objective of this study is to evaluate the safety and effectiveness of the Endoluminal Surgical (ELS) System in subjects undergoing specified transanal endoluminal procedures in the rectum and sigmoid colon. Subjects will undergo endoscopic submucosal dissection (ESD), with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.\n\nThe safety and effectiveness outcomes will be assessed intraoperatively and postoperatively at discharge and Days 7 and 30.",[174,114,28,175,176,145,177,178],"Colorectal Lesion","Rectal Lesion","Rectal Adenoma","Sigmoid; Lesion","Sigmoid Colon Polyp",[175,180],"Sigmoid Lesion","2026-04-09",{"date":183,"type":61},"2026-04-14",{"date":185,"type":61},"2025-05-13",{"date":187,"type":22},"2026-06",{"name":189,"class":190},"EndoQuest Robotics, Inc.","INDUSTRY",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":17,"sex":18,"minAge":198,"maxAge":77,"enrollmentInfo":199,"targetDuration":4,"studyType":80,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":98},"100518558","feasibility-and-colorectal-benefits-of-pulses-supplementation-100518558","NCT06032104","Feasibility and Colorectal Benefits of Pulses Supplementation","Feasibility of Pulses Supplementation in Healthy Adults: A Feeding Study","Inclusions:\n\n1. 30-80 years-old\n2. Overweight or obesity (body mass index ≥ 25 kg\u002Fm2)\n3. Planned for a standard of care colonoscopy for colon cancer screening\n\nExclusions:\n\n1. Intolerance to a bean or high bean consumer based on a screening survey\n2. Pregnancy or actively planning to get pregnant\n3. Any active gastrointestinal disease resulting in disturbed gut function or malabsorption (e.g., chronic diarrhea or inflammatory bowel disease)\n4. Current or history of any malignancy in the past 10 years.\n5. Chronic use of opioids, anti-inflammatory drugs, antibiotics, prebiotics, or probiotics within 1 month of study endpoints\n6. History of a significant systemic condition (e.g., heart disease, chronic kidney disease, liver dysfunction or immune suppression), or abnormal laboratory markers (e.g., abnormal liver enzymes, creatinine, clotting factors, or low platelets count). The severity of the intolerance to fiber\u002F the medical conditions\u002Flab markers and eligibility will be defined after the careful interview of the patient\u002Freview of the medical records by Dr. Hussan)","30 Years",{"count":200,"type":22},25,[82],"Beans are a forgotten staple food that shows promise in improving health. The goal of this study is to look at how bean supplementation affects metabolic and bowel health. In the long-term, the investigators believe this research will lead to a better understanding of the impact of beans on bowel health. The investigators also hope that this research study will help us understand ways to improve human diet and prevent colon cancer in the future.",[28,204],"Obesity","2025-12-03",{"date":207,"type":61},"2025-12-05",{"date":209,"type":61},"2023-10-27",{"date":211,"type":22},"2026-09",{"name":213,"class":68},"University of California, Davis",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":80,"phases":224,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":98},"100530943","detection-of-endoscopic-resection-scars-and-delineation-of-recurrence-is-trainable-100530943","NCT06193356","Detection of Endoscopic Resection Scars and Delineation of Recurrence is Trainable","Detection of Endoscopic Resection Scars and Delineation of Recurrence Amongst Non-experts is Less Accurate Than Experts But Trainable in a Short Learning Intervention","SCAR","Inclusion Criteria:\n\n* Endoscopists of any experience level\n\nExclusion Criteria:\n\n* non consenting adults",{"count":223,"type":22},141,[82],"Colorectal cancer is prevented by colonoscopy and polypectomy. Failure to recognize the endoscopic resection scar after Endoscopic Mucosal Resection (EMR) risks unrecognized recurrent or residual adenoma (RRA), which may propagate into post-colonoscopy colorectal cancer. Expert series suggest scar recognition and interrogation is well performed with a high negative predictive value of endoscopic imaging vs histopathology. In this study the authors will investigate the performance of endoscopic imaging in detecting RRA at an endoscopic resection scar amongst general endoscopist and the impact of a learning intervention on recognition of RRA.\n\nAfter consent is given, the participant will open the online survey and fill this in.\n\nFirst the participant will be asked to create a pseudonym (name+year of birth) and fill in their demographical information (Grade, years in current role, colonoscopy experience, experience of colonic tissue resection, country of employment\n\nThe first 15 pictures will be shown prior to a learning intervention. For each picture the same questions will be asked:\n\n* Is this an endoscopic resection scar?\n* Based on this image does the scar demonstrate evidence of residual or recurrent adenoma (RRA)?\n* What is your level of confidence?\n* If the scar shows RRA, how would you treat it? (skip if you feel no RRA).\n* If the scar does not show RRA do you feel there is another diagnosis? After the first 15 pictures a video-based learning tool will be shown on detection of RRA.\n\nAfter the learning tool 15 different pictures will be shown, the same questions will be asked. All responses will be collected by the investigators. Statistical analysis will be performed using visual studio code (Microsoft, Redmond, USA) Images will be selected from the 'Australian Colonic LSL Endoscopic Resection Study' (ACE) database, which is an international multicentre registry of images and videos for retrospective analysis of colonic lesions. Images, videos, procedural information, and histopathological data are stored on a secure online web portal after written informed consent of every participating patient.",[28,26],[228,229,230,231],"endoscopy","advanced imaging","post-colonoscopy colorectal cancer","Colorectal polypectomy","2025-11-19",{"date":234,"type":61},"2025-11-25",{"date":236,"type":61},"2024-11-11",{"date":238,"type":22},"2027-01-01",{"name":240,"class":68},"University Hospital, Ghent",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":80,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":98},"100515218","performance-and-safety-of-miwendo-assisted-colonoscopy-miwendo-ii-100515218","NCT05988645","Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)","Performance and Safety of MiWEndo-assisted Colonoscopy: MiWEndo II (Pivotal Study)","Inclusion Criteria:\n\n\\- Patients with a previously detected polyp in the rectum referred for resection.\n\nThese criteria will ensure the probability of finding polyps during the explorations.\n\nAll the patients will give written informed consent.\n\nExclusion Criteria:\n\n* Patients at a high risk of having major complications as perforation or hemorrhage, suspected or proven lower gastrointestinal bleeding, non-correctable coagulopathy or anticoagulant\u002Fclopidogrel therapy during procedure, inadequate bowel cleansing.\n* ASA-IV patients.\n* Urgent colonoscopy.",{"count":249,"type":22},50,[82],"The study involves the planned use of a new microwave-based device during colonoscopy procedures in 50 patients to assess the performance and safety of its use for detection of colorectal polyps and lack of normal clinical practice modification. The device is a final design version, which has been previously tested in several preclinical studies (including phantom studies, an ex vivo study with human tissues, and an in vivo study with porcine model) and in a pilot study in humans (NCT05477836)",[26,28,114,42,29,27],[254,255,256,257],"microwave imaging","colonoscopy","early diagnosis","colorectal cancer screening","2025-09-23",{"date":260,"type":61},"2025-09-29",{"date":262,"type":61},"2023-08-01",{"date":264,"type":22},"2025-12-29",{"name":266,"class":190},"MiWEndo Solutions S.L.",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":18,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":98},"100589685","development-and-validation-of-microbiota-and-metabolite-based-prediction-model-for-recurrence-of-high-risk-colorectal-polyps-after-polypectomy-100589685","NCT06957626","Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy","Inclusion Criteria:\n\n* patients aged 40-75 years who undergo the colonoscopy with at least 1 advanced premalignant polyps or ≥ 3 adenoma\n\nExclusion Criteria:\n\n* patient with severe physical diseases that prevented them from adhering to the examination requirements,\n* patient with coagulopathy or other contraindications for biopsy or polypectomy,\n* patient with previous surgical procedures on the gastrointestinal tract,\n* presence of colorectal cancer or other malignant tumor at baseline\n* presence of inflammatory bowel disease or hereditary polyposis syndromes (such as family adenomatous polyposis or Lynch syndrome)\n* within 1 month before enrollment, oral antibiotics and probiotics were taken;\n* inability to provide informed consent or refusal to participate in the study.","40 Years","75 Years",{"count":276,"type":22},150,"The characteristics of the intestinal microbiota in high-risk colorectal polyp recurrence and their relationship with disease pathogenesis have not yet been fully elucidated. This study aims to analyze the microbial community characteristics in the intestinal mucosal tissue of patients after polypectomy with recurrence of colorectal polyps. Additionally, this research holds significant importance for understanding the etiology of adenoma recurrence and develop a microbiota and metabolite-based predicting tool.",[28,279,114],"Colorectal Cancer Recurrent","2025-06-29",{"date":282,"type":61},"2025-07-01",{"date":284,"type":61},"2023-04-25",{"date":153,"type":22},{"name":287,"class":68},"Peking Union Medical College Hospital",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":80,"phases":297,"briefSummary":298,"conditions":299,"keywords":302,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":98},"100442445","cold-snare-endoscopic-mucosal-resection-emr-vs-cold-emr-with-margin-snare-tip-soft-coagulation-stsc-100442445","NCT05041478","Cold Snare Endoscopic Mucosal Resection (EMR) vs Cold EMR With Margin Snare Tip Soft Coagulation (STSC)","Cold Snare Endoscopic Mucosal Resection vs Cold Snare Endoscopic Mucosal Resection With Adjuvant Thermal Therapy to Resection Margins - A Randomised Controlled Trial","Inclusion Criteria:\n\n* Any patient undergoing colonoscopy who is older than 18 years of age, has a written consent for trial participation and has at least one laterally spreading lesion meeting the following description:\n* Localisation in the colon or rectum\n* Benign adenomatous surface features (Kudo III \u002F IV, Japan NBI Expert Team (JNET) 2a)\n* Granular or non-granular topography\n* Paris classification 0-IIa\u002FIIb +\u002F- Is\n* If present, sessile component may be no greater than 10mm in size.\n* Polyp size ranging from 15 to 40mm\n\nExclusion Criteria:\n\n* Current use of antiplatelet (excluding aspirin) or anticoagulants which have not appropriately been interrupted according to the guidelines.\n* Known bleeding disorder or coagulopathy.\n* Pregnancy\n* History of inflammatory bowel disease\n* Previously attempted or otherwise non-lifting lesions\n* Endoscopic features suggestive of submucosal invasion (Kudo Vi\u002Fn, JNET 2b \u002F 3) or concurrent colorectal cancer\n* Lesions involving the ileocaecal valve (ICV), appendiceal oriface or anorectal junction (ARJ)",{"count":296,"type":22},300,[82],"Randomised controlled trial comparing cold snare endoscopic mucosal resection (EMR) with cold snare EMR and adjuvant margin STSC in the complete resection of 15-40mm lateral-spreading adenomas",[28,300,301],"Colon Adenoma","Colon Cancer",[117,52,303,26],"Adenoma","2025-03-25",{"date":306,"type":61},"2025-03-27",{"date":308,"type":61},"2023-09-19",{"date":310,"type":22},"2028-10-01",{"name":312,"class":68},"Western Sydney Local Health District",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":98},"100576908","clinical-study-on-the-accuracy-of-real-time-ai-assisted-endocytoscopy-in-the-diagnosis-of-colorectal-diminutive-polyps-100576908","NCT06791408","Clinical Study on the Accuracy of Real-time AI-assisted Endocytoscopy in the Diagnosis of Colorectal Diminutive Polyps","Inclusion Criteria:\n\n* colorectal lesions\n\nExclusion Criteria:\n\n* lesions lacking high-quality images;\n* Inflammatory bowel disease, familial adenomatous polyposis and other special diseases;\n* submucosal tumors;\n* Pathological diagnosis of inflammatory polyps, Peutz-Jeghers polyps, juvenile polyps, lymphoma and other pathological types.",{"count":320,"type":22},600,"Colorectal cancer (CRC) is the third most common malignant tumor in the world and the second largest cause of cancer-related death \\[1\\]. Colonoscopy is considered the preferred method of screening for colorectal cancer, and early and resectable detection of colorectal neoplastic lesions can significantly reduce colorectal cancer morbidity and mortality. In recent years, with the continuous development of endoscopic diagnostic techniques and the standardization and strengthening of endoscopist training, the detection rate of colorectal polyps has increased year by year. As the number of endoscopic excisions increases, the costs associated with endoscopic excision and pathological diagnosis of excised specimens increase year by year. Research results showed that about 90% of the detected polyps were small polyps (6-9 mm) and diminutive polyps (≤5 mm), and nearly half of them were non-neoplastic polyps, so endoscopic resection and histopathological examination were not required \\[2, 3\\]. In order to reduce unnecessary pathological examination and endoscopic treatment, the American Society of Digestive Endoscopy proposed PIVI strategies: \"excise and discard\" and \"diagnose and do not excise\" strategies.\n\nEndocytoscopy is a kind of ultra-high magnification endoscopy. Combined with chemical staining and narrow-band imaging technology, endoscopists can observe and judge the nuclear morphology, glandular duct morphology and microvascular morphology of colorectal lesions by naked eye, thus realizing the purpose of real-time biopsy in vivo. However, it takes a lot of experience accumulation to improve the judgment accuracy of endoscopy images, and endoscopy doctors have certain subjective judgments and errors in the process of judging results. Therefore, in order to solve this problem, Artificial Intelligence (AI) is proposed clinically. Our center has developed an artificial intelligence assisted diagnosis system based on endocytoscopy to assist endocytoscopy in judging the nature of colorectal lesions. However, whether this artificial intelligence assisted diagnosis system is accurate in judging the nature of colorectal diminutive polyps and is suitable for widespread promotion and application of PIVI strategy lacks relevant clinical data. This study intends to carry out this clinical study to verify the diagnostic accuracy of this artificial intelligence in the diagnosis of colorectal diminutive polyps.",[28],"2025-03-05",{"date":325,"type":61},"2025-03-07",{"date":327,"type":61},"2025-02-05",{"date":329,"type":22},"2025-12-31",{"name":331,"class":68},"The First Hospital of Jilin University",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":17,"sex":18,"minAge":340,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":348,"leadSponsor":350,"locationsCount":4},"100488128","clinical-performance-of-the-mainz-biomed-colorectal-cancer-screening-test-for-colorectal-cancer-and-advanced-adenoma-100488128","NCT05636085","Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer and Advanced Adenoma","Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for the Detection of Colorectal Cancer and Advanced Adenoma in an Average Risk Population","reconAAsense","Inclusion Criteria:\n\n1. Subject is any sex and ≥45 years of age\n2. Subject must be advised to have or be scheduled for a screening colonoscopy\n3. Subject is at average risk for colorectal cancer according to the United States Preventive Services Task Force (USPSTF) guidelines, including:\n\n   * no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease\n   * no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer including:\n\n     * Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease\n     * Familial adenomatous polyposis (also referred to as \"FAP\", including attenuated FAP)\n     * Hereditary non-polyposis colorectal cancer syndrome (also referred to as \"HNPCC\" or \"Lynch Syndrome\")\n     * Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis and Familial Hyperplastic Polyposis\n     * Cronkhite Canada Syndrome\n4. Subject can understand the study procedures and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a Health Insurance Portability and Accountability Act (HIPAA) medical release form\n5. Subject is able and willing to provide stool samples within ninety (90) days before the colonoscopy procedure\n6. Subject is able and willing to undergo a colonoscopy after providing a stool sample\n\nExclusion Criteria:\n\n1. Subject had any precancerous findings on most recent colonoscopy.\n2. Subject has a history of abnormal imaging suggesting colorectal cancer (e.g., colonography, MRI, CT, barium enema)\n3. Subject has a history of any of the following cancers: oral, head and neck, lung, esophagus, gastric, biliary\u002Fliver, pancreatic, small bowel, or appendiceal\n4. Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals\n\n   * High-sensitivity fecal occult blood test or fecal immunochemical test within the previous twelve (12) months\n   * sDNA-FIT test within the previous thirty-six (36) months\n5. Subject has had a colonoscopy in the previous nine (9) years\n6. Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease\n7. Indication for colonoscopy due to overt rectal bleeding (e.g., hematochezia or melena) within the previous thirty (30) days\n8. Subject has any condition that in the opinion of the investigator should preclude participation in the study","45 Years",{"count":342,"type":22},15000,"This study is to determine how the Mainz Biomed Colorectal Cancer Screening Test works when used in people aged ≥45 years of age and at an average risk of developing colorectal cancer.",[26,27,28,114],"2025-03-03",{"date":323,"type":61},{"date":329,"type":22},{"date":349,"type":22},"2027-09-01",{"name":351,"class":190},"Mainz Biomed",{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":80,"phases":363,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":98},"100571064","evaluation-of-a-cam-system-for-colorectal-polyp-size-measurement-100571064","NCT06715384","Evaluation of a CAM System for Colorectal Polyp Size Measurement","Performance Evaluation of a Computer-aided Measuring System for Colorectal Polyp Size Measurement: a Prospective Study","CAM","Inclusion Criteria:\n\n1. Adults aged 18-75, any gender; 76-85 years eligible case-by-case based on health status.\n2. Colonoscopy screening, surveillance, or diagnostic participants.\n3. Informed consent obtained.\n\nExclusion Criteria:\n\n1. Anticoagulant use (e.g., aspirin, warfarin) within 7 days prior to colonoscopy or coagulopathy.\n2. Inflammatory bowel disease.\n3. Aronchick score \\>3 at entry.\n4. Incomplete Case Report Form (CRF) data.\n5. Emergency colonoscopy.\n6. Pregnancy or lactation.\n7. Gastrointestinal obstruction.\n8. Refusal to participate.","85 Years",{"count":362,"type":22},168,[82],"Accurate polyp size measurements are essential for risk stratification, selection of polypectomy techniques, and surveillance interval assignments. Evidence indicated that the clinical implementation of artificial intelligence is an optimal tool to improve the measurement of polyps during colonoscopy. This study aimed to evaluate the performance of a computer-aided measuring (CAM) system (EndoDASS) and compare its accuracy with routine sizing methods during real-time colonoscopy.",[28,114],[50,367,368,117,369],"Polyp Size","Deep Learning","Depth Map","2025-02-15",{"date":372,"type":61},"2025-02-19",{"date":374,"type":61},"2024-12-15",{"date":376,"type":22},"2025-04-30",{"name":378,"class":68},"Changhai Hospital",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":388,"conditions":389,"keywords":394,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":98},"100444184","early-diagnosis-real-time-healthcare-system-for-cancer-trial-100444184","NCT05064124","Early DiAgnosis Real-Time Healthcare System for CANcer Trial","EARTHSCAN","Inclusion Criteria:\n\n* Participants scheduled to undergo a screening, surveillance or symptomatic colonoscopy with an endoscopist participating in the study phase of the trial.\n* Male and female participants aged 18 years or older at the time of informed consent.\n* Participants able to comprehend, sign and date the written informed consent document to participate in the study.\n\nExclusion Criteria:\n\n* Emergency and\u002For inpatient colonoscopies\n* Participants with inflammatory bowel disease (IBD)\n* Participants with current Colorectal Cancer (CRC)\n* Participants with a contraindication for biopsy or polypectomy. These include:\n\n  * Participants who have not withheld medications pre-disposing to bleeding at time of colonoscopy as per local site \u002Fnational guidelines.\n  * Participants with a history of haemostasis disorders (haemostasis disorders will include but will not be limited to: participants with haemophilia or other congenitally acquired clotting factor deficiencies, participants with cirrhosis with coagulopathy, participants known to have thrombocytopenia (\\\u003C80,000 platelet\u002Ful) and individuals with Von Willebrand's disease or other known platelet malfunction disorders)\n* Participant is enrolled in another research study with an investigational medicinal product (IMP) or non-IMP that pre-disposes them to bleeding",{"count":387,"type":22},420,"The purpose of the study is to assess whether the AI characterisation system of the CADDIE device improves the endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps in the bowel during colonoscopy. Participants will either have a colonoscopy with the assistance of the CADDIE device characterisation AI system (\"intervention group\") or have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system (\"control group\"). The randomisation method of this trial will allocate enrolled participants to the \"intervention\" group and to the \"control\" group by a technique similar to flipping a coin.",[390,391,28,392,393],"Polyps","Adenoma Colon","Colon Polyp","Polyps of Colon",[395,396,397],"Artificial intelligence","Endoscopy","ADR","2024-12-10",{"date":400,"type":61},"2024-12-16",{"date":402,"type":61},"2024-07-18",{"date":404,"type":22},"2025-05",{"name":406,"class":68},"University College, London",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":18,"minAge":414,"maxAge":415,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":435},"100550874","early-diagnosis-of-colorectal-cancer-based-on-a-non-invasive-metabolomics-profile-100550874","NCT06452745","Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile","EarlyCRC","Inclusion Criteria:\n\n* Patients with a positive FOBT test result from the Colorectal Cancer Early Detection Program and referred for a colonoscopy.\n\nExclusion Criteria:\n\n* Patients diagnosed with another primary neoplasm in the last 5 years, with the exception of carcinoma in situ of the cervix or non-melanoma skin cancer.\n* Patients with severe kidney disease stage IV (creatinine clearance \\\u003C 30 ml\u002Fmin).\n* Patients with severe active liver disease (hepatitis, cirrhosis).\n* Refusal to sign informed consent.","50 Years","70 Years",{"count":21,"type":22},"Colorectal cancer is the most frequent tumor in our environment if both sexes are considered together. Every year almost 800 cases are diagnosed in the districts of Tarragona. A little more than half of colorectal cancers are cured with surgery, with or without the addition of complementary treatments with chemotherapy and\u002For radiation therapy. Those who are not cured is because at the time of diagnosis the disease has already spread or they spread after having been treated surgically with curative intent.\n\nThe purpose of the EarlyCRC project is to determine whether metabolites (substances of low molecular weight) can be found in the urine and stool of patients with colorectal cancer or polyps that can be easily and cheaply differentiated (urine or stool analysis) between the patients affected by colorectal cancer or polyps, from healthy individuals. For the identification of these possible metabolites, the urine analysis will be performed using the usual techniques in metabolomics, which studies the existing metabolites in biological processes.",[26,114,28,419],"Healthy",[421,422,423,424,425],"screening","urine","fobt","biomarkers","metabolomics","2024-09-30",{"date":428,"type":61},"2024-10-02",{"date":430,"type":61},"2019-07-20",{"date":432,"type":22},"2040-06-30",{"name":434,"class":68},"Institut Investigacio Sanitaria Pere Virgili",2,{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":445,"conditions":446,"keywords":448,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":98},"100450335","diagnostic-accuracy-of-m3-in-predicting-colorectal-advanced-adenoma-recurrence-m3-aa-100450335","NCT05144152","Diagnostic Accuracy of M3 in Predicting Colorectal Advanced Adenoma Recurrence (M3-AA)","A Prospective Study to Assess the Diagnostic Accuracy of a Panel of Bacterial Gene Markers (M3) in Predicting Colorectal Advanced Adenoma Recurrence","M3-AA","Inclusion Criteria:\n\n1. Known colorectal adenomas during index colonoscopy;\n2. Available baseline M3 and FIT results before index colonoscopy;\n3. Aged ≥18 years old;\n4. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Refusal or unfit to undergo surveillance colonoscopy;\n2. Incomplete colonoscopy, incomplete removal of colorectal adenomas, or inadequate bowel preparation (defined as Boston Bowel Preparation Scale score 0 or 1 in any colonic segment) at index colonoscopy;\n3. Previous colonic resection;\n4. Personal history of colorectal cancer;\n5. Personal history of polyposis syndrome;\n6. Personal history of inflammatory bowel disease;\n7. Known pregnancy or lactation;\n8. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);",{"count":320,"type":22},"The investigators aim to evaluate the diagnostic accuracy of FIT and the novel panel of four bacterial gene markers collectively named as M3, to detect recurrent advanced adenomas in patients with history of colonic adenomas.",[114,447,28],"Advanced Adenoma",[449,450,117],"FIT","Bacterial marker","2024-08-26",{"date":453,"type":61},"2024-08-27",{"date":455,"type":61},"2021-12-13",{"date":457,"type":22},"2025-06-15",{"name":459,"class":68},"Chinese University of Hong Kong",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":469,"conditions":470,"keywords":473,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":98},"100554716","bile-acids-and-microbiome-in-early-colorectal-carcinogenesis-100554716","NCT06502704","Bile Acids and Microbiome in Early Colorectal Carcinogenesis","Bile Acids and Microbiome - Possible Novel Progression Factors and Diagnostic Indicators in Early Colorectal Carcinogenesis","Inclusion Criteria:\n\n\\- Patients that have clinical indications for colonoscopy\n\nExclusion Criteria:\n\n* Pregnancy\n* Immunocompromised\n* Previously diagnosed colorectal diseases\n* Radiotherapy to the pelvis\n* Long term antibiotic use within 6 months\n* Continuous use of proton pump inhibitors",{"count":468,"type":22},60,"Currently colorectal cancer pathogenesis is mainly explained by the adenoma-carcinoma sequence theory that was proposed more than half a century ago. It mainly focuses on the explanation of genetic mutations that develop throughout the disease course. However, several studies argue that there are also noticeable bile acid metabolism changes and microbiome composition changes within in colorectal cancer patients. However, carcinoma is the final step in the sequence, and prior steps are noticeably less well studied. Thus, the investigators hypothesize, that changes within microbiome and the changes in the urine, serum and gut bile acid composition further leads to the development of colorectal adenoma and subsequent invasive carcinoma.\n\nAdult participants (15 per group) referred for colonoscopy and histologically diagnosed with small (\\\u003C1cm) adenomas, large (\\>1cm) adenomas, invasive CRC will be included in the study, as well as 15 healthy controls. Fecal samples will be collected from all participants before bowel preparation. Additionally, urine and serum samples will be collected. Participants will undergo polypectomy, endoscopic mucosal resections, depending on the location, size and histology of the polyp found. During colonoscopy the mucosal biopsy specimens from the lesion and from the healthy bowel -terminal ileum, and colon will be obtained using sterile biopsy forceps. The collected samples will be stored for bile acid and microbiome analysis and for possible further pathology and genetic testing. Healthy participants without visible colorectum pathology during colonoscopy will undergo colon and terminal ileum mucosal sampling.\n\nThe investigators plan to evaluate the correlation between the urine and gut microbiome changes and bile acid composition and concentration in adenoma-carcinoma sequence and possibly determine novel bile acids. In addition, fecal, urine and tissue samples will be explored for gut microbiota and bile acid composition changes in healthy and along the adenoma-carcinoma sequence, with the possibility to propose a diagnostic test.",[27,26,28,471,472],"Microbiome","Bile Acid Malabsorption",[27,26,28,471,474],"Bile Acid","2024-07-08",{"date":477,"type":61},"2024-07-16",{"date":479,"type":22},"2024-07-05",{"date":481,"type":22},"2025-01-01",{"name":483,"class":68},"Vilnius University",{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":98},"100550433","artificial-intelligence-development-for-colorectal-polyp-diagnosis-100550433","NCT06447012","Artificial Intelligence Development for Colorectal Polyp Diagnosis","Development of a Novel Real Time Computer Assisted Colonoscopy Diagnostic Tool for Colorectal Polyps: Lesion Diagnosis and Personalised Patient Management","Inclusion Criteria:\n\n\\- Above 18 years at inclusion Symptomatic or screening colonoscopy\n\nExclusion Criteria:\n\n* Unable to provide informed consent.\n* Colitis Associated Dysplasia\n* Polyps at surgical anastomosis sites\n* Pregnancy",{"count":492,"type":22},4000,"Accurate classification of growths in the large bowel (polyps) identified during colonoscopy is imperative to inform the risk of colorectal cancer. Reliable identification of the cancer risk of individual polyps helps determine the best treatment option for the detected polyp and determine the appropriate interval requirements for future colonoscopy to check the site of removal and for further polyps elsewhere in the bowel.\n\nCurrent advanced endoscopic imaging techniques require specialist skills and expertise with an associated long learning curve and increased procedure time. It is for these reasons that despite being introduced in clinical practice, uptake of such techniques is limited and current methods of polyp risk stratification during colonoscopy without Artificial intelligence (AI) is suboptimal. Approximately 25% of bowel polyps that are removed by major surgery are analysed and later proved to be non-cancerous polyps that could have been removed via endoscopy thus avoiding anatomy altering surgery and the associated risks. With accurate polyp diagnosis and risk stratification in real time with AI, such polyps could have been removed non-surgically (endoscopically). Current Computer Assisted Diagnosis (CADx, a form of AI) platforms only differentiate between cancerous and non cancerous polyps which is of limited value in providing a personalised patient risk for colorectal cancer. The development of a multi-class algorithm is of greater complexity than a binary classification and requires larger training and validation datasets. A robust CADx algorithm should also involve global trainable data to minimise the introduction of bias. It is for these reasons that this is a planned international multicentre study.\n\nThe Investigators aim to develop a novel AI five class pathology prediction risk prediction tool that provides reliable information to identify cancer risk independent of the endoscopists skill.\n\nThese 5 categories are chosen because treatment options differ according to the polyp type and future check colonoscopy guidelines require these categories",[495,28],"Polyp of Colon",[50,497,498,499,49],"Computer assisted diagnosis (CADx)","Colorectal cancer","Colorectal polyp","2024-06-05",{"date":502,"type":61},"2024-06-06",{"date":504,"type":61},"2024-05-04",{"date":506,"type":22},"2026-05-30",{"name":508,"class":68},"King's College Hospital NHS Trust",{"id":510,"slug":511,"hasResults":11,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":80,"phases":519,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":4},"100521286","robotic-right-hemicolectomy-versus-laparoscopic-right-hemicolectomy-100521286","NCT06067620","Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy","Robotic Right Hemicolectomy With Intracorporeal Anastomosis Versus Laparoscopic Right Hemicolectomy With Extracorporeal Anastomosis (PRORHEM): a Randomized Controlled Trial","PRORHEM","Inclusion Criteria:\n\n* Adult patients requiring elective minimally invasive RHC for cT1-T3 Nx M0 cancer of the right colon (including cancer of the appendix, caecum, ascending colon and hepatic flexure).\n\nExclusion Criteria:\n\n* Not scheduled for minimally invasive RHC (refuses surgery and\u002For planned open approach)\n* Emergency surgery\n* Hereditary colorectal cancer\n* Inflammatory bowel disease\n* Synchronous resection of (an)other organ(s)\n* Synchronous surgical procedure (including more extended resection of the lower gastrointestinal tract)\n* cT4\n* cM+\n* History of laparotomy\n* Pregnancy\n* No anastomosis planned\n* Unable to provide informed consent\n* No informed consent",{"count":518,"type":22},70,[82],"Robotic right hemicolectomy with intra-corporeal anastomosis may have better short-term recovery outcomes and decreased incidence of incisional hernia when compared to the laparoscopic actual standard of care, for similar safety outcomes.",[27,36,522,26,28,114,29],"Colorectal Neoplasms, Benign","2024-05-09",{"date":525,"type":61},"2024-05-10",{"date":527,"type":22},"2024-08-01",{"date":529,"type":22},"2026-12-31",{"name":531,"class":68},"Jeremy Meyer",{"id":533,"slug":534,"hasResults":11,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":540,"conditions":541,"keywords":542,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":98},"100386144","safety-of-colorectal-assessment-and-tumor-evaluation-by-colon-capsule-endoscopy-100386144","NCT04307901","Safety Of ColoRectal Assessment and Tumor Evaluation by Colon Capsule Endoscopy","SOCRATEC","Inclusion Criteria:\n\n* Incomplete colonoscopy, referral for colonoscopy under general anesthesia or declining colonoscopy after completion of bowel preparation.\n\nExclusion Criteria:\n\n* Chrohn's disease with symptoms of stenosis and\u002For pacemaker",{"count":320,"type":22},"Following European guidelines patients undergoing colonoscopy in one of Odense University Hospitals units will now be offered a colon capsule endoscopy (CCE) in case of incomplete examinations. Patients formerly referred to colonoscopy in general anesthesia or patients who decline colonoscopy after having completed bowel preparation will also be offered a CCE. In our department we have conducted a comparison study documenting that the sensitivity of CCE is superior to CT colonography in both polyps \\>9 mm and polyps \\>5 mm, which is also supported by an Italian study. The safety and completion rate of CCE following incomplete colonoscopy is confirmed by several studies including one multicenter study and the completion rate is not significantly lower compared to other patient groups. In an incomplete colonoscopy it is always the most oral part of the colon which is not visualized, whereas in CCE, an incomplete investigation will most often have visualized the oral part. By combining incomplete colonoscopy results and incomplete CCE results we can identify patients who have had a complete colon investigation although both investigations were incomplete.\n\nAim: to investigate the quality of CCE and the completion rate in patients who have undergone an incomplete colonoscopy, have completed bowel preparation but declines colonoscopy or have been referred to colonoscopy in general anesthesia.",[26,28],[543,544,255,228],"colon capsule endoscopy","ct colonography","2020-05-18",{"date":547,"type":61},"2020-05-20",{"date":549,"type":61},"2020-05-01",{"date":551,"type":22},"2030-12-31",{"name":553,"class":68},"Odense University Hospital"]